KROS stock forecast, quote, news & analysis
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
Keros Therapeutics (KROS) Stock Analysis: Rinvatercept Pipeline Momentum Against Uneven Revenue
Key Takeaways
- KROS shares have moved only modestly over the past 30 days, trading in a relatively narrow range near $11 after a steep decline earlier in 2026.
- Keros is a clinical-stage biopharmaceutical company with no marketed products, so revenue remains tied to irregular collaboration and milestone payments.
- A $20 million milestone from Takeda followed first-patient dosing in the Phase III ELRiSE study of elritercept.
- The company's lead internal asset, rinvatercept, is advancing in Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), with initial Phase II DMD data expected in the first half of 2027.
- Analyst consensus sits at Moderate Buy with an average price target around $18.80, while cash of $257.6 million is projected to fund operations into the first half of 2028.
Current Market Snapshot
Keros Therapeutics (KROS) has traded in a comparatively stable range in recent weeks after a challenging stretch earlier in the year. Over the last 30 days, the stock has fluctuated between roughly $10.65 and $12.24, holding close to the $11 level and registering only a small single-digit percentage change from mid-September. That relative calm contrasts with a broader downtrend in 2026, when shares gave back a substantial portion of their value as investors reassessed a pipeline that generates no recurring product revenue.
Sentiment remains cautious but constructive. Analysts covering the stock maintain a Moderate Buy consensus, with firms such as Wells Fargo carrying a Buy rating and a $18 price target. The company's valuation multiples are elevated relative to peers given its pre-revenue status, which keeps execution on clinical milestones central to the investment case.
Keros Therapeutics (KROS) Business Overview and Competitive Position
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. The company positions itself as a leader in understanding how TGF-β proteins regulate the growth, repair, and maintenance of tissues including skeletal muscle, bone, blood vessels, heart tissue, and blood cells.
Keros' most advanced product candidate, elritercept, is in late-stage development for cytopenias — including anemia and thrombocytopenia — in myelodysplastic syndromes and myelofibrosis. Takeda holds exclusive worldwide development and commercialization rights outside mainland China, Hong Kong, and Macau, and has assumed much of the associated development cost.
The company's lead internal asset, rinvatercept, is being developed for DMD and ALS. Phase I results in healthy volunteers demonstrated increases in muscle mass and bone mineral density alongside reduced fat mass, supporting advancement into Phase II testing. In the competitive DMD landscape, established players such as Sarepta Therapeutics (SRPT) and PTC Therapeutics (PTCT) represent meaningful benchmarks for any new entrant.
Recent Developments Driving KROS
Several verified developments have shaped investor sentiment in recent weeks. Keros announced it will receive a $20 million development milestone from Takeda after the first patient was dosed in the Phase III ELRiSE study of elritercept, which evaluates the candidate against epoetin alfa for anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. The company expects to distribute 25% of the net cash proceeds to stockholders, with the remainder supporting its wholly owned rinvatercept program.
The milestone underscores both the partnership's progress and Keros' dependence on collaboration income. The company recorded no revenues in the second quarter of 2026 and generated only $0.37 million in first-half revenues, reflecting the lumpy timing of milestone recognition. Research and development expenses fell sharply year over year as elritercept costs transitioned to Takeda.
On the pipeline front, Keros initiated its Phase II study of rinvatercept in DMD, with initial data still expected in the first half of 2027. The company also plans to engage regulators in the second half of 2026 on the design of a Phase II study in ALS. Financial flexibility remains intact: cash and cash equivalents totaled $257.6 million at June 30, 2026, with management guiding a runway into the first half of 2028.
Trending AI Robots
For traders seeking a systematic approach to stocks like KROS, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only top-performing and most relevant bots are surfaced in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches aligned with different risk tolerances and holding periods. Browsing the section can provide useful context on how quantitative models are currently positioning across the market.
2026 Outlook and What Investors Should Watch
Looking ahead, Keros' trajectory will hinge largely on clinical execution. The most significant upcoming checkpoint is initial data from the Phase II DMD study of rinvatercept, expected in the first half of 2027, along with regulatory discussions on the ALS program. Positive readouts could meaningfully broaden the company's opportunity, while any delays or setbacks would concentrate risk on a single lead asset.
Investors should also monitor cash consumption, given the runway into the first half of 2028 and the absence of recurring product revenue. Additional Takeda milestones — up to $1.1 billion in potential development, commercial, and sales payments plus tiered royalties — remain a source of non-dilutive funding, but their timing is unpredictable. Competitive developments in the DMD and hematology spaces, broader biotech sentiment, and the pace of institutional positioning will also influence the stock. As with any clinical-stage company, KROS carries substantial execution and binary clinical risk that should be weighed carefully.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for KROS shows an upward move is likely
KROS's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 226 similar instances where the Aroon Indicator showed a similar pattern. In 194 of the 226 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 55 cases where KROS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
KROS moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 227 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 75 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 30 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.853) is normal, around the industry mean (3.035). P/E Ratio (-3.503) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology